You searched for: Spago Nanomedical

Spago Nanomedical decides on rights issue of SEK 25 million

Spago Nanomedical shows proof-of-concept for Tumorad

Spago’s CEO comments on Proof-of-Concept milestone

Spago Nanomedical has reported a positive outcome following the Data Monitoring Committee (DMC) review of the results to date in the...

Spago Nanomedical demonstrates tumor uptake in phase I/IIa study

Spago stays on schedule – green light for phase I/IIa study

Following a positive safety review, Spago Nanomedical's Phase I/IIa study has been granted permission to continue at the highest current dose level. The study is progressing...

Spago takes Tumorad-01 study to the next level

Spago Nanomedical has increased the dose of its cancer drug candidate 177Lu-SN201 in its phase I/IIa Tumorad-01 study, following...

Spago's CEO: “We want to expand cancer treatment with effective radiopharmaceuticals”

2024 has marked a defining chapter for Spago Nanomedical, solidifying its position in radionuclide therapy. By focusing its energy...

Investing in life science: From Seed to Success 2024

Last week, investors and entrepreneurs gathered at the World Trade Center in Stockholm for "Investing in Life Science: From Seed...

Spago Nanomedical strengthened management to reflect project progress

The clinical phase I/IIa study evaluating radiopharmaceutical candidate 177Lu-SN201 in solid tumors has been progressing steadily for Spago Nanomedical....

Spago's CEO: Advancing the tumor program comes first

Spago Nanomedical's Q1 report signals steady progress with its radiopharma pipeline. Lead program Tumorad recently got a boost by...

Spago Nanomedical's CEO: “huge commercial opportunities are unfolding”

Last week we saw the USD 2 billion buyout of Fusion Pharmaceuticals by AstraZeneca to accelerate the development of...

2023 springboard for Spago's radionuclide cancer therapy

In 2023, Swedish biotech Spago Nanomedical kicked off its journey in the clinic with radionuclide cancer therapy Tumorad. Ending...